Conversation with The Cancer Letter After 25 years as FDA’s chief cancer strategist, Richard Pazdur reflects on opportunities for change at the agency January 10, 2025Vol.51 No.01By Paul Goldberg
Clinical Roundup Rybrevant + Lazcluze show improvement in OS versus osimertinib January 10, 2025Vol.51 No.01
Drugs & Targets FDA clears IND application for Recursion’s LSD1 inhibitor REC-4539 January 10, 2025Vol.51 No.01
Clinical Roundup Starpax announces magnetic field-controlled bacteria that deliver drugs to solid tumors June 28, 2024Vol.50 No.26
Drugs & Targets Secarna, Orbit collaborate to develop peptide-conjugated targeted ASO therapeutics May 31, 2024Vol.50 No.22
Clinical Roundup Setanaxib combination improves PFS and OS in SCCHN in phase II trial May 10, 2024Vol.50 No.19
Clinical Roundup PRMT5 inhibitor combination overcomes drug resistance in ER+ breast cancer April 26, 2024Vol.50 No.17
Clinical Roundup UCLA: Adding ribociclib to hormone therapy reduces the risk of breast cancer recurrence March 29, 2024Vol.50 No.13
Drugs & Targets FDA grants Augtyro priority review for NTRK-positive locally advanced or metastatic solid tumors February 16, 2024Vol.50 No.07
In Brief The Max Foundation provides targeted treatment for advanced breast cancer patients in Mozambique at no cost November 10, 2023Vol.49 No.42
